
China Approves In-House Anti-Insomnia Drug DAYVIGO
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito, announced a significant milestone in its global expansion strategy with…